Ascendis Pharma A/S (ASND)

Ascendis Pharma Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	494.05	559.54	392.16	444.77	446.27	584.52
Short-Term Investments	-	-	7.28	290.69	235.8	134.28
Cash & Short-Term Investments	494.05	559.54	399.44	735.46	682.06	718.8
Cash Growth	90.98%	40.08%	-45.69%	7.83%	-5.11%	20.18%
Accounts Receivable	110.45	166.28	35.87	11.91	2.2	0.39
Other Receivables	10.77	11.16	19.9	13.72	20.99	6.96
Receivables	121.22	177.44	55.77	25.63	23.19	7.34
Inventory	303.38	295.61	208.93	130.67	75.41	-
Prepaid Expenses	34.31	28.27	38.58	31.72	25.23	13.99
Total Current Assets	952.96	1,061	702.72	923.47	805.89	740.13
Property, Plant & Equipment	93.54	98.71	110.63	129.1	126.05	108.11
Long-Term Investments	34.9	13.58	5.69	30.42	145.91	124.46
Goodwill	-	3.5	3.5	-	3.5	3.5
Other Intangible Assets	3.79	0.53	0.92	4.83	1.78	2.22
Other Long-Term Assets	2.71	2.32	2.13	1.92	1.81	1.38
Total Assets	1,088	1,179	825.59	1,090	1,085	979.79
Accounts Payable	93.72	96.39	94.57	101.03	59.42	21.9
Accrued Expenses	39.92	67.96	41.18	31.99	29.95	23.38
Current Portion of Long-Term Debt	447.08	476.05	407.1	399.19	-	-
Current Portion of Leases	15.27	15.48	14.17	13.79	7	6.86
Current Income Taxes Payable	0.71	1.22	2.3	5.49	0.2	0.3
Current Unearned Revenue	1.79	0.94	1.18	-	2.6	0.36
Other Current Liabilities	336.51	249.82	176.02	165.29	1.19	-
Total Current Liabilities	935	907.86	736.51	716.78	100.36	52.8
Long-Term Debt	254.53	287.53	138.38	-	-	-
Long-Term Leases	75.66	77.55	84.62	95.4	97.97	85.12
Long-Term Unearned Revenue	0.69	5	5.95	14.21	2.96	-
Long-Term Deferred Tax Liabilities	9.6	7.26	5.83	-	-	-
Other Long-Term Liabilities	-	-	-	-	-	3.16
Total Liabilities	1,275	1,285	971.28	826.39	201.29	141.08
Common Stock	8.21	8.15	7.75	7.68	7.65	7.22
Additional Paid-In Capital	2,470	2,444	2,123	2,113	2,108	1,729
Retained Earnings	-2,666	-2,560	-2,277	-1,860	-1,236	-1,030
Treasury Stock	-0.08	-0.11	-0.15	-0.15	-0.02	-
Comprehensive Income & Other	0.31	1.78	0.72	3.45	3.78	133.03
Shareholders' Equity	-187.57	-105.71	-145.7	263.35	883.64	838.71
Total Liabilities & Equity	1,088	1,179	825.59	1,090	1,085	979.79
Total Debt	792.53	856.62	644.27	508.38	104.96	91.98
Net Cash (Debt)	-298.49	-297.07	-244.83	234.57	684.66	742.1
Net Cash Growth	-	-	-	-65.74%	-7.74%	32.17%
Net Cash Per Share	-5.02	-5.13	-4.35	4.18	12.50	14.66
Filing Date Shares Outstanding	60.55	59.84	56.61	56.04	56.78	53.75
Total Common Shares Outstanding	60.55	59.84	56.61	56.04	56.78	53.75
Working Capital	17.96	153	-33.79	206.69	705.53	687.33
Book Value Per Share	-3.10	-1.77	-2.57	4.70	15.56	15.60
Tangible Book Value	-191.36	-109.73	-150.12	258.52	878.36	832.99
Tangible Book Value Per Share	-3.16	-1.83	-2.65	4.61	15.47	15.50
Machinery	-	32.91	38.86	-	25.77	19.8
Leasehold Improvements	-	20.3	19.38	-	18.07	8.54

Updated May 1, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q